1. Home /
  2. Biotechnology


Options Play of the Week: A Mid-Cap Biopharma in the Crosshairs

Acadia is a good sum-of-the-parts story with bad news mostly priced in and potential positive catalysts on the near-term horizon.

Why Are Insiders Buying These 2 Beaten Down Small-Cap Biopharmas?

Eyenovia and BioDelivery Sciences are their targets.

Moderna's Patent Credit, Palantir and ARK, Musk Sells Tesla as EV Stocks Climb

Plus, the intersection of rising inflation and a slowing velocity of money give us reason for pause.

Traders Should Be Stopped Out of Biohaven Pharmaceutical

For now I would take a wait and see approach.

I See a Direction for Compass Pathways

It may have a tough pill to swallow right now, but I'm still optimistic about psilocybin in general, and especially Cybin.

Putting Together an End-of-Year Trading Strategy

Let's review areas that are hot, those that are not, and how to position though January.

GT Biopharma Must Learn How to Play the Game ... and Explain Itself

Let's look at the rookie mistake the biopharma made on Monday, and what makes the company still hold promise for investors -- if it explains its C-suite moves.

Moderna's Shots Block COVID, but Its Shares Now Have Risky Side Effects

Let's see how far this pharma name could fall, even as it plays a leading role in the battle against the pandemic.

Let's Improvise as iRhythm Technologies Heads into Earnings

I'm going to offer a cautious trade on this name.

Options Play of the Week: Wash, Rinse, Repeat

BioMarin has turned into a synthetic dividend play that has been returning yields in the low teens every six months or so.